Breakthrough in oncology: Siberian scientists patent an affordable rapid test for leukemia for regional areas
Siberian scientists have patented a rapid diagnostic system for aggressive blood cancer
Russian researchers have developed and patented a set of artificial DNA fragments (primers) for the rapid detection of key genetic mutations in acute myeloid leukemia (AML). This innovation will allow doctors to quickly determine the disease prognosis, tailor personalized therapy, and subsequently monitor minimal residual disease.
Acute myeloid leukemia is one of the most aggressive forms of blood cancer, with a five-year survival rate not exceeding 26%. In such cases, every day counts: treatment must begin immediately, meaning molecular tumor profiling results are urgently needed by clinicians. However, existing genetic testing methods often take too long. Moreover, they require expensive equipment and highly specialized personnel, making them largely inaccessible to most ordinary clinics.
The new Russian development radically changes this situation. The patented set allows the completion of complex genetic analysis within just two days, using standard laboratory equipment produced in Russia.
"The invention relates to the field of medicine, specifically genetics and molecular biology. It can be used in oncology and hematology for the rapid detection of major clinically significant mutations on standard domestic equipment in widespread clinical practice," the patent documentation states.
The technology was developed by specialists from the Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences and Novosibirsk State Medical University (NSMU), with support from the Novosibirsk company Biosintez. Using specialized software, scientists modeled primer pairs to detect six of the most significant mutations associated with AML. The efficacy of the innovation was tested at the Novosibirsk City Hematology Center on a sample of 128 patients. The testing results fully matched global statistics on mutation frequency. Moreover, during clinical trials, two patients displayed previously undescribed genetic insertion variants.
According to the developers, this fact has fundamental scientific and practical significance: it demonstrates that the created set can detect not only mutations already known to science but also entirely new, previously unrecorded variants.
Who is affected
Точное выявление мутаций помогает подобрать терапию, которая будет эффективна именно для конкретного пациента, и избежать ненужных токсичных воздействий неэффективных препаратов.
Объективный, быстрый и доступный локальный тест на мутации дает четкие, неоспоримые данные. Это защищает пациента с ОВЗ от врачебных ошибок и предвзятости, давая ему в руки конкретный инструмент для защиты своего права на правильное лечение.
